2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parikh, C. R. Articles by McSweeney, P. Search for Related Content PubMed PubMed Citation Articles by Parikh, C. R. Articles by McSweeney, P.

Acute Renal Failure after Nonmyeloablative Hematopoietic Cell Transplantation

Chirag R. Parikh^*, Brenda M. Sandmaier, Rainer F. Storb, Karl G. Blume, Firoozeh Sahebi, David G. Maloney, Michael B. Maris, Yago Nieto^||, Charles L. Edelstein^*, Robert W. Schrier^* and Peter McSweeney^||

*Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado; Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington; Division of Bone Marrow Transplantation, Stanford University, Stanford, California; Division of Hematology and Oncology, City of Hope National Medical Center, Duarte, California; and ^||Division of Hematology and Oncology, University of Colorado Health Sciences Center, Denver, Colorado

Correspondence to Dr. Robert Schrier, 4200 E Ninth Avenue, Box 173, Denver, CO 80262. Phone: 303-315-8059; Fax: 303-315-4852; E-mail: Robert.Schrier{at}uchsc.edu

ABSTRACT. Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy ± fludarabine 30 mg/m². Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50% decrease in GFR) occurred in 40.4% of patients over a 3-mo period, with 4.4% of patients requiring dialysis. The overall mortality in the study population was 34% at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80%. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.

This article has been cited by other articles:

				R. Khoriaty, Z. K. Otrock, W. A. Medawar, R. B. Khauli, and A. Bazarbachi A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3585 - 3588. [Full Text] [PDF]

				M. J. Ellis, U. D. Patel, M. Ende, F. I. Ende, and E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., September 7, 2006; 355(10): 1070 - 1070. [Full Text] [PDF]

				M. T. Nevessignsky and A. Ferster Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1154 - 1157. [Full Text] [PDF]

				R. W. Schrier and C. R. Parikh Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation Nephrol. Dial. Transplant., April 1, 2005; 20(4): 678 - 683. [Full Text] [PDF]

				B. D. Humphreys, R. J. Soiffer, and C. C. Magee Renal Failure Associated with Cancer and Its Treatment: An Update J. Am. Soc. Nephrol., January 1, 2005; 16(1): 151 - 161. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673